Blue Water Life Science Fund

Overview

Blue Water Life Science Fund focuses on venture and growth equity investments in the life sciences sector, with a geographic reach spanning North America, Europe, and Asia. The firm evaluates opportunities in biotechnology, pharmaceuticals, medical devices, and diagnostics. By maintaining offices in key global life science clusters including Ann Arbor, San Francisco, Basel, and Singapore, Blue Water positions itself to access proprietary deal flow and deep scientific networks. The investment strategy prioritizes companies developing transformative therapies and platform technologies. Blue Water typically participates in early-stage and growth-stage financings, often working alongside specialist life science venture firms and corporate venture arms. The firm's multi-hub structure allows it to diligence assets in both established and emerging biotech markets. No specific portfolio companies or fund sizes have been publicly confirmed as of mid-2026. Team size and assets under management are not publicly disclosed. Philanthropic or adjacent vehicles have not been publicly identified in connection with the firm. Blue Water's structural anchor is its geography. Instead of concentrating in a single biotech capital, the firm maintains a deliberately distributed presence that mirrors the global nature of life science innovation — a model that differs from Boston- or San Francisco-centric peers. This architecture supports a sourcing funnel that draws from multiple academic, hospital, and entrepreneurial ecosystems simultaneously.